Use of Aspirin and Statin as primary prevention for cardiovascular diseases

Alkhail, Bahaa Aba; Iftikhar, Rahila; Shaikh, Adnan Al

doi:10.12669/pjms.326.10615

Cited by 8 publications

(10 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This mechanism leads to various derangements in the lipid metabolism resulting in various dyslipidemias. 19 In our present study, 20,21 As per the general age group involved in T2DM, almost all our patients (95.4%) were 40 plus, with nearly 61% in 50-69-years of age group. In our study, for diabetic patients, the odds of having comorbidities are 7.33 and 20.14 times higher in the age group 60-69 years and 70-79 years, respectively, as the odds for age less than 40 years having comorbidities.…”

Section: Discussionsupporting

confidence: 47%

<p>Association of Dyslipidemia and Comorbidities with Risk Factors Among Diabetic Patients: A Retrospective Analysis</p>

Gazzaz¹,

Iftikhar²,

Jameel³

et al. 2020

DMSO

Self Cite

View full text Add to dashboard Cite

Purpose: To find out the association of dyslipidemia and comorbidities with risk factors among type-2 diabetes mellitus (T2DM) patients attending King Abdulaziz University Hospital (KAUH) Jeddah, Saudi Arabia (SA). Patients and Methods: Three hundred and twenty-five T2DM patients were enrolled from the electronic record of the KAUH. The patients' existing comorbidities and dyslipidemia correlation with demographic, clinical, and available laboratory data were sought. Statistical analysis was performed on SPSS-23. Results: Of the total 325 T2DM patients with a mean age of 60.13±10.5 years [males 95 (29.23%) and females 230 (70.77%)] were included from the electronic record. Poor glycemic control was observed in 222 (68.31%) subjects (HbA1c > 7%), and 154 (47.39%) subjects had DM for more than ten years. Among our study subjects, 103 (31.69%) were hypertensive (HTN), 112 (34.46%) had ischemic heart disease (IHD), 45 (13.85%) were obese, 8(2.46%) had a stroke and 269 (82.77%) had dyslipidemia. Of the total 269 dyslipidemic patients,168 (62.45%) were on hypolipidemic treatment. On comparison of study variables according to dyslipidemia versus normal lipid levels, the lipid profile, including HDLc, LDLc, TC, and TG, revealed a highly significant difference (p-value <0.001) whereas many variables were not significantly different. HBA1c, FBG, and RBG were significantly higher in dyslipidemic subjects. Logistic regression analysis of risk factors and comorbidities in our patients revealed that age 60-69 years and 70-79 years had a significant association with comorbidities. Similarly, logistic regression analysis of risk factors and dyslipidemia in our patients revealed no statistically significant association. Conclusion: Our results observed that the comorbidities were associated with increasing age and common comorbidities were HTN, IHD, dyslipidemia. Our study has highlighted the current trends in T2DM symptomatology and comorbidities. Efficient management and control by early screening and developing healthy lifestyles in our patients can be very helpful in the prevention of all these highly morbid complications of this preventable disease.

show abstract

Section: Discussionsupporting

confidence: 47%

<p>Association of Dyslipidemia and Comorbidities with Risk Factors Among Diabetic Patients: A Retrospective Analysis</p>

Gazzaz¹,

Iftikhar²,

Jameel³

et al. 2020

DMSO

Self Cite

View full text Add to dashboard Cite

show abstract

“…It has been reported that aspirin primarily inhibits cyclooxygenase-1 irreversibly and reduces the synthesis of thromboxane A2, which prevents platelet aggregation and thrombosis. [ 16 ] Clopidogrel, ticlopidine, and cilostazol are other antiplatelet agents used to treat or prevention of cardiovascular diseases. Anticoagulant agents, such as warfarin, dabigatran, and rivaroxaban, act as vitamin K antagonists in clinical use.…”

Section: Discussionmentioning

confidence: 99%

Safety of transrectal ultrasound-guided prostate biopsy in patients receiving aspirin

et al. 2021

View full text Add to dashboard Cite

Background: The management of aspirin before transrectal prostate puncture-guided biopsy continues to be controversial. The conclusions in newly published studies differ from the published guideline. Therefore, an updated meta-analysis was performed to assess the safety of continuing to take aspirin when undergoing a transrectal ultrasound-guided prostate biopsy (TRUS-PB). Methods: We searched the following databases for relevant literature from their inception to October 30, 2020: PubMed, EMBASE, Cochrane Central Register of Controlled Trials, Medline, Web of Science, Sinomed, Chinese National Knowledge Internet, and WANGFANG. Studies that compared the bleeding rates between aspirin that took aspirin and non-aspirin groups were included. The quality of all included studies was evaluated using the Newcastle-Ottawa Scale. Revman Manger version 5.2 software was employed to complete the meta-analysis to assess the risk of hematuria, hematospermia, and rectal bleeding. Results: Six articles involving 3373 patients were included in this meta-analysis. Our study revealed that compared with the non-aspirin group, those taking aspirin exhibited a higher risk of rectal bleeding after TRUS-PB (risk ratio [RR] = 1.27, 95% confidence interval [CI] [1.09–1.49], P = .002). Also, the meta-analysis results did not reveal any significant difference between the 2 groups for the risk of hematuria (RR = 1.02, 95%CI [0.91–1.16], P = .71) and hematospermia (RR = 0.93, 95%CI [0.82–1.06], P = .29). Conclusion: Taking aspirin does not increase the risk of hematuria and hematospermia after TRUS-PB. However, the risk of rectal bleeding, which was slight and self-limiting, did increase. We concluded that it was not necessary to stop taking aspirin before undergoing TRUS-PB.

show abstract

“…Similar study was done at different region of Saudi Arabia to evaluate the recommendation of aspirin as well as statin treatment in patients with diabetes to prevent CVD. This study found that aspirin was indicated and prescribed in 36.2% of the patients while in aspirin was indicated but not recommended in 17.0% of the patients ( Alkhail et al, 2016 ).…”

Section: Introductionmentioning

confidence: 94%

“…Aspirin has been approved by the U.S. food and drug administration (FDA) to be use as secondary prevention agent of cardiovascular diseases (CVD) ( Durlaza-prescribing information, 2015 ). Its advantage was significantly noticeable in decreasing CVD morbidity and mortality in patients with high risk of CVD or those underwent CVD procedures ( Bryant, et al, 2006 , Algra and Rothwell, 2012 , Williams et al, 2015 , Alkhail et al, 2016 , Abdelaziz et al, 2019 ). Several randomized clinical controlled trials have assessed the role of aspirin as primary prevention agent.…”

Section: Introductionmentioning

confidence: 99%